Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

References

1. 1.↵
   2. Strebhardt K,
   3. Ullrich A.

   Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8: 473–80.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   2. Cruz E,
   3. Kayser V.

   Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019; 13: 33–51.

   OpenUrlPubMed
3. 3.
   2. Maeda H,
   3. Khatami M.

   Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Trans Med. 2018; 7: 11.

   OpenUrl
4. 4.
   2. Adler MJ,
   3. Dimitrov DS.

   Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012; 26: 447–81, vii.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Tolcher AW.

   Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016; 27: 2168–72.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Hernandez I.

   Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018; 24: 109–12.

   OpenUrl
7. 7.↵
   2. Yan L,
   3. Ehrlich PJ,
   4. Gibson R,
   5. Pickett C,
   6. Beckman RA.

   How can we improve antibody-based cancer therapy? mAbs. 2009; 1: 67–70.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.
   2. Choudhury N,
   3. Nakamura Y.

   Importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016; 107: 107–15.

   OpenUrl
9. 9.↵
   2. Coats S,
   3. Williams M,
   4. Kebble B,
   5. Dixit R,
   6. Tseng L,
   7. Yao NS, et al.

   Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019; 25: 5441–8.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    2. Baselga J.

    Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients? Nat Rev Clin Oncol. 2005; 2: 284–5.

    OpenUrl
11. 11.
    2. Perez EA,
    3. Baehner FL,
    4. Butler SM,
    5. Thompson EA,
    6. Dueck AC,
    7. Jamshidian F, et al.

    The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in alliance n9831. Breast Cancer Res. 2015; 17: 133.
12. 12.↵
    2. Davis AA,
    3. Patel VG.

    The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7: 278.
13. 13.↵
    2. Glassman PM,
    3. Balthasar JP.

    Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014; 11: 20–33.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Gül N,
    3. van Egmond M.

    Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015; 75: 5008–13.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Golay J,
    3. Taylor RP.

    The role of complement in the mechanism of action of therapeutic anti-cancer mAbs. Antibodies. 2020; 9: 58.

    OpenUrl
16. 16.↵
    2. Sun C,
    3. Mezzadra R,
    4. Schumacher TN.

    Regulation and function of the PD-L1 checkpoint. Immunity. 2018; 48: 434–52.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Baxter LT,
    3. Jain RK.

    Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989; 37: 77–104.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    2. Baxter LT,
    3. Jain RK.

    Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res. 1990; 40: 246–63.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.
    2. Chauhan VP,
    3. Stylianopoulos T,
    4. Boucher Y,
    5. Jain RK.

    Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011; 2: 281–98.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Jain RK.

    Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990; 9: 253–66.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.
    2. Jain RK.

    Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990; 50: 814s–9s.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    2. Jain RK.

    Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987; 47: 3039–51.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    2. Jain RK,
    3. Baxter LT.

    Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48: 7022–32.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    2. Jain RK.

    Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987–9.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    2. Jain RK.

    Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58–62.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    2. Thurber GM,
    3. Zajic SC,
    4. Wittrup KD.

    Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007; 48: 995–9.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    2. Huang Y,
    3. Stylianopoulos T,
    4. Duda DG,
    5. Fukumura D,
    6. Jain RK.

    Benefits of vascular normalization are dose and time dependent – letter. Cancer Res. 2013; 73: 7144–6.

    OpenUrlFREE Full Text
28. 28.↵
    2. Abuqayyas L,
    3. Balthasar JP.

    Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J. 2012; 14: 445–55.

    OpenUrlPubMed
29. 29.↵
    2. Baker JHE,
    3. Kyle AH,
    4. Reinsberg SA,
    5. Moosvi F,
    6. Patrick HM,
    7. Cran J, et al.

    Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment. Clin Exp Metastasis. 2018; 35: 691–705.

    OpenUrl
30. 30.
    2. Pastuskovas CV,
    3. Mundo EE,
    4. Williams SP,
    5. Nayak TK,
    6. Ho J,
    7. Ulufatu S, et al.

    Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012; 11: 752–62.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    2. Arjaans M,
    3. Oude Munnink TH,
    4. Oosting SF,
    5. Terwisscha van Scheltinga AG,
    6. Gietema JA,
    7. Garbacik ET, et al.

    Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013; 73: 3347–55.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    2. Zhao M,
    3. Pan X,
    4. Layman R,
    5. Lustberg MB,
    6. Mrozek E,
    7. Macrae ER, et al.

    A phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs. 2014; 32: 1285–94.

    OpenUrl
33. 33.↵
    2. Chung TK,
    3. Warram J,
    4. Day KE,
    5. Hartman Y,
    6. Rosenthal EL.

    Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther. 2015; 16: 790–8.

    OpenUrl
34. 34.↵
    2. Heskamp S,
    3. Boerman OC,
    4. Molkenboer-Kuenen JD,
    5. Oyen WJ,
    6. van der Graaf WT,
    7. van Laarhoven HW.

    Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer. 2013; 133: 307–14.

    OpenUrlCrossRefPubMed
35. 35.↵
    2. Saltz L,
    3. Badarinath S,
    4. Dakhil S,
    5. Bienvenu B,
    6. Harker WG,
    7. Birchfield G, et al.

    Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. Folfox-bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2012; 11: 101–11.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    2. Hecht JR,
    3. Mitchell E,
    4. Chidiac T,
    5. Scroggin C,
    6. Hagenstad C,
    7. Spigel D, et al.

    A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27: 672–80.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    2. Sandler A,
    3. Gray R,
    4. Perry MC,
    5. Brahmer J,
    6. Schiller JH,
    7. Dowlati A, et al.

    Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006; 355: 2542–50.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.
    2. Miller K,
    3. Wang M,
    4. Gralow J,
    5. Dickler M,
    6. Cobleigh M,
    7. Perez EA, et al.

    Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666–76.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    2. Tewari KS,
    3. Sill MW,
    4. Long HJ,
    5. Penson RT,
    6. Huang H,
    7. Ramondetta LM, et al.

    Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370: 734–43.

    OpenUrlCrossRefPubMed
40. 40.↵
    2. Thurber GM,
    3. Weissleder R.

    A systems approach for tumor pharmacokinetics. PLoS One. 2011; 6: e24696.
41. 41.↵
    2. Netti PA,
    3. Hamberg LM,
    4. Babich JW,
    5. Kierstead D,
    6. Graham W,
    7. Hunter GJ, et al.

    Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A. 1999; 96: 3137–42.

    OpenUrlAbstract/FREE Full Text
42. 42.
    2. Folli S,
    3. Pelegrin A,
    4. Chalandon Y,
    5. Yao X,
    6. Buchegger F,
    7. Lienard D, et al.

    Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993; 53: 829–36.

    OpenUrlPubMed
43. 43.↵
    2. Li J,
    3. Merton DA,
    4. Duggaraju R,
    5. Thakur ML.

    Augmenting of tumor uptake of anti-melanoma antibody MEM136: influence of interferon. Nucl Med Biol. 1996; 23: 873–9.

    OpenUrlCrossRefPubMed
44. 44.↵
    2. LeBerthon B,
    3. Khawli LA,
    4. Alauddin M,
    5. Miller GK,
    6. Charak BS,
    7. Mazumder A, et al.

    Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 1991; 51: 2694–8.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    2. Khawli LA,
    3. Miller GK,
    4. Epstein AL.

    Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer. 1994; 73: 824–31.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    2. Epstein AL,
    3. Mizokami MM,
    4. Li J,
    5. Hu P,
    6. Khawli LA.

    Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003; 95: 741–9.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    2. Roth L,
    3. Prahst C,
    4. Ruckdeschel T,
    5. Savant S,
    6. Weström S,
    7. Fantin A, et al.

    Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci Signal. 2016; 9: ra42.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    2. Sugahara KN,
    3. Teesalu T,
    4. Karmali PP,
    5. Kotamraju VR,
    6. Agemy L,
    7. Greenwald DR, et al.

    Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328: 1031–5.

    OpenUrlAbstract/FREE Full Text
49. 49.↵
    2. Shin TH,
    3. Sung ES,
    4. Kim YJ,
    5. Kim KS,
    6. Kim SH,
    7. Kim SK, et al.

    Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther. 2014; 13: 651–61.

    OpenUrlAbstract/FREE Full Text
50. 50.↵
    2. Serlin Y,
    3. Shelef I,
    4. Knyazer B,
    5. Friedman A.

    Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol. 2015; 38: 2–6.

    OpenUrlCrossRefPubMed
51. 51.↵
    2. Razpotnik R,
    3. Novak N,
    4. Čurin Šerbec V,
    5. Rajcevic U.

    Targeting malignant brain tumors with antibodies. Front Immunol. 2017; 8: 1181.
52. 52.↵
    2. Cavaco M,
    3. Gaspar D,
    4. Arb Castanho M,
    5. Neves V.

    Antibodies for the treatment of brain metastases, a dream or a reality? Pharmaceutics. 2020; 12: 62.

    OpenUrl
53. 53.↵
    2. Chang H-Y,
    3. Morrow K,
    4. Bonacquisti E,
    5. Zhang W,
    6. Shah DK.

    Antibody pharmacokinetics in rat brain determined using microdialysis. mAbs. 2018; 10: 843–53.

    OpenUrl
54. 54.↵
    2. Wang Q,
    3. Delva L,
    4. Weinreb PH,
    5. Pepinsky RB,
    6. Graham D,
    7. Veizaj E, et al.

    Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS. 2018; 15: 10.

    OpenUrl
55. 55.↵
    2. Arvanitis CD,
    3. Ferraro GB,
    4. Jain RK.

    The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020; 20: 26–41.

    OpenUrl
56. 56.↵
    2. Dijkers EC,
    3. Oude Munnink TH,
    4. Kosterink JG,
    5. Brouwers AH,
    6. Jager PL,
    7. de Jong JR, et al.

    Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586–92.

    OpenUrlCrossRefPubMed
57. 57.↵
    2. Jansen MH,
    3. Veldhuijzen van Zanten SEM,
    4. van Vuurden DG,
    5. Huisman MC,
    6. Vugts DJ,
    7. Hoekstra OS, et al.

    Molecular drug imaging: 89Zr-bevacizumab pet in children with diffuse intrinsic pontine glioma. J Nucl Med. 2017; 58: 711–6.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    2. Neuwelt EA,
    3. Barnett PA,
    4. Hellström KE,
    5. Hellström I,
    6. McCormick CI,
    7. Ramsey FL.

    Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med. 1994; 35: 1831–41.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    2. Ningaraj NS,
    3. Rao M,
    4. Hashizume K,
    5. Asotra K,
    6. Black KL.

    Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002; 301: 838–51.

    OpenUrlAbstract/FREE Full Text
60. 60.↵
    2. Ningaraj NS,
    3. Sankpal UT,
    4. Khaitan D,
    5. Meister EA,
    6. Vats TS.

    Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Cancer Biol Ther. 2009; 8: 1924–33.

    OpenUrlPubMed
61. 61.↵
    2. Kinoshita M,
    3. McDannold N,
    4. Jolesz FA,
    5. Hynynen K.

    Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006; 103: 11719–23.

    OpenUrlAbstract/FREE Full Text
62. 62.↵
    2. Park E-J,
    3. Zhang Y-Z,
    4. Vykhodtseva N,
    5. McDannold N.

    Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release. 2012; 163: 277–84.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    2. Liu H-L,
    3. Hsu P-H,
    4. Lin C-Y,
    5. Huang C-W,
    6. Chai W-Y,
    7. Chu P-C, et al.

    Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016; 281: 99–108.

    OpenUrlCrossRefPubMed
64. 64.↵
    2. Brighi C,
    3. Reid L,
    4. White AL,
    5. Genovesi LA,
    6. Kojic M,
    7. Millar A, et al.

    MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neuro-Oncol Adv. 2020; 2.
65. 65.↵
    2. Pulgar VM.

    Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci. 2019; 12.
66. 66.
    2. Paterson J,
    3. Webster CI.

    Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016; 20: 49–52.

    OpenUrl
67. 67.↵
    2. Pardridge WM.

    Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015; 12: 207–22.

    OpenUrl
68. 68.↵
    2. Regina A,
    3. Demeule M,
    4. Tripathy S,
    5. Lord-Dufour S,
    6. Currie J-C,
    7. Iddir M, et al.

    ANG4043, a novel brain-penetrant peptide–mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther. 2015; 14: 129–40.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    2. Nounou MI,
    3. Adkins CE,
    4. Rubinchik E,
    5. Terrell-Hall TB,
    6. Afroz M,
    7. Vitalis T, et al.

    Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in-vivo study. Pharm Res. 2016; 33: 2930–42.

    OpenUrl
70. 70.↵
    2. Brown LF,
    3. Dvorak AM,
    4. Dvorak HF.

    Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis. 1989; 140: 1104–7.

    OpenUrlCrossRefPubMedWeb of Science
71. 71.↵
    2. Nieskoski MD,
    3. Marra K,
    4. Gunn JR,
    5. Hoopes PJ,
    6. Doyley MM,
    7. Hasan T, et al.

    Collagen complexity spatially defines microregions of total tissue pressure in pancreatic cancer. Sci Rep. 2017; 7: 10093.
72. 72.↵
    2. Davies CL,
    3. Berk DA,
    4. Pluen A,
    5. Jain RK.

    Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer. 2002; 86: 1639–44.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    2. Dolor A,
    3. Szoka Jr FC.

    Digesting a path forward: the utility of collagenase tumor treatment for improved drug delivery. Mol Pharm. 2018; 15: 2069–83.

    OpenUrlCrossRef
74. 74.
    2. Eikenes L,
    3. Tufto I,
    4. Schnell EA,
    5. Bjorkoy A,
    6. De Lange Davies C.

    Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res. 2010; 30: 359–68.

    OpenUrlAbstract/FREE Full Text
75. 75.
    2. Magzoub M,
    3. Jin S,
    4. Verkman AS.

    Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008; 22: 276–84.

    OpenUrlCrossRefPubMedWeb of Science
76. 76.
    2. Choi J,
    3. Credit K,
    4. Henderson K,
    5. Deverkadra R,
    6. He Z,
    7. Wiig H, et al.

    Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin Cancer Res. 2006; 12: 1906–12.

    OpenUrlAbstract/FREE Full Text
77. 77.↵
    2. Netti PA,
    3. Berk DA,
    4. Swartz MA,
    5. Grodzinsky AJ,
    6. Jain RK.

    Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000; 60: 2497–503.

    OpenUrlAbstract/FREE Full Text
78. 78.↵
    2. Brown E,
    3. McKee T,
    4. diTomaso E,
    5. Pluen A,
    6. Seed B,
    7. Boucher Y, et al.

    Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9: 796–800.

    OpenUrlCrossRefPubMedWeb of Science
79. 79.↵
    2. Eikenes L,
    3. Bruland OS,
    4. Brekken C,
    5. Davies CL.

    Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004; 64: 4768–73.

    OpenUrlAbstract/FREE Full Text
80. 80.↵
    2. Brekken C,
    3. Hjelstuen MH,
    4. Bruland OS,
    5. de Lange Davies C.

    Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res. 2000; 20: 3513–9.

    OpenUrlPubMed
81. 81.↵
    2. Thompson CB,
    3. Shepard HM,
    4. O’Connor PM,
    5. Kadhim S,
    6. Jiang P,
    7. Osgood RJ, et al.

    Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010; 9: 3052–64.

    OpenUrlAbstract/FREE Full Text
82. 82.↵
    2. Singha NC,
    3. Nekoroski T,
    4. Zhao C,
    5. Symons R,
    6. Jiang P,
    7. Frost GI, et al.

    Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther. 2015; 14: 523–32.

    OpenUrlAbstract/FREE Full Text
83. 83.
    2. Jacobetz MA,
    3. Chan DS,
    4. Neesse A,
    5. Bapiro TE,
    6. Cook N,
    7. Frese KK, et al.

    Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62: 112–20.

    OpenUrlAbstract/FREE Full Text
84. 84.↵
    2. Infante JR,
    3. Korn RL,
    4. Rosen LS,
    5. LoRusso P,
    6. Dychter SS,
    7. Zhu J, et al.

    Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018; 118: 153–61.

    OpenUrl
85. 85.↵
    2. Mookerjee I,
    3. Unemori EN,
    4. Du XJ,
    5. Tregear GW,
    6. Samuel CS.

    Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann N Y Acad Sci. 2005; 1041: 190–3.

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    2. Mookerjee I,
    3. Hewitson TD,
    4. Halls ML,
    5. Summers RJ,
    6. Mathai ML,
    7. Bathgate RAD, et al.

    Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009; 23: 1219–29.

    OpenUrlCrossRefPubMedWeb of Science
87. 87.↵
    2. Beyer I,
    3. Li Z,
    4. Persson J,
    5. Liu Y,
    6. van Rensburg R,
    7. Yumul R, et al.

    Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther. 2011; 19: 479–89.

    OpenUrlCrossRefPubMed
88. 88.↵
    2. Lee K-C,
    3. Hsieh Y-C,
    4. Chan C-C,
    5. Sun H-J,
    6. Huang Y-H,
    7. Hou M-C, et al.

    Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. Lab Invest. 2019; 99: 1203–16.

    OpenUrl
89. 89.
    2. Blessing WA,
    3. Okajima SM,
    4. Cubria MB,
    5. Villa-Camacho JC,
    6. Perez-Viloria M,
    7. Williamson PM, et al.

    Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis. Proc Natl Acad Sci U S A. 2019; 116: 12183–92.

    OpenUrlAbstract/FREE Full Text
90. 90.↵
    2. Ikeda Y,
    3. Zabbarova IV,
    4. Birder LA,
    5. Wipf P,
    6. Getchell SE,
    7. Tyagi P, et al.

    Relaxin-2 therapy reverses radiation-induced fibrosis and restores bladder function in mice. Neurourol Urodyn. 2018; 37: 2441–51.

    OpenUrl
91. 91.↵
    2. Metra M,
    3. Teerlink JR,
    4. Cotter G,
    5. Davison BA,
    6. Felker GM,
    7. Filippatos G, et al.

    Effects of serelaxin in patients with acute heart failure. N Engl J Med. 2019; 381: 716–26.

    OpenUrl
92. 92.↵
    2. Chen SA,
    3. Perlman AJ,
    4. Spanski N,
    5. Peterson CM,
    6. Sanders SW,
    7. Jaffe R, et al.

    The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res. 1993; 10: 834–8.

    OpenUrlCrossRefPubMed
93. 93.↵
    2. Muppidi A,
    3. Lee SJ,
    4. Hsu C-H,
    5. Zou H,
    6. Lee C,
    7. Pflimlin E, et al.

    Design and synthesis of potent, long-acting lipidated relaxin-2 analogs. Bioconjugate Chem. 2019; 30: 83–9.

    OpenUrl
94. 94.↵
    2. Sun J,
    3. Hao W,
    4. Fillmore N,
    5. Ma H,
    6. Springer D,
    7. Yu ZX, et al.

    Human relaxin-2 fusion protein treatment prevents and reverses isoproterenol-induced hypertrophy and fibrosis in mouse heart. J Am Heart Assoc. 2019; 8: e013465.
95. 95.↵
    2. Binder C,
    3. Chuang E,
    4. Habla C,
    5. Bleckmann A,
    6. Schulz M,
    7. Bathgate R, et al.

    Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain. Clin Exp Metastasis. 2014; 31: 57–65.

    OpenUrlCrossRefPubMed
96. 96.↵
    2. Ma J,
    3. Niu M,
    4. Yang W,
    5. Zang L,
    6. Xi Y.

    Role of relaxin-2 in human primary osteosarcoma. Cancer Cell Int. 2013; 13: 59.

    OpenUrl
97. 97.↵
    2. Hu M,
    3. Wang Y,
    4. Xu L,
    5. An S,
    6. Tang Y,
    7. Zhou X, et al.

    Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019; 10: 2993.
98. 98.↵
    2. Chauhan VP,
    3. Martin JD,
    4. Liu H,
    5. Lacorre DA,
    6. Jain SR,
    7. Kozin SV, et al.

    Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4: 2516.
99. 99.↵
    2. Scales SJ,
    3. de Sauvage FJ.

    Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009; 30: 303–12.

    OpenUrlCrossRefPubMedWeb of Science
100. 100.↵
     2. Liu J,
     3. Liao S,
     4. Diop-Frimpong B,
     5. Chen W,
     6. Goel S,
     7. Naxerova K, et al.

     TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012; 109: 16618–23.

     OpenUrlAbstract/FREE Full Text
101. 101.↵
     2. Panagi M,
     3. Voutouri C,
     4. Mpekris F,
     5. Papageorgis P,
     6. Martin MR,
     7. Martin JD, et al.

     TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020; 10: 1910–22.

     OpenUrl
102. 102.↵
     2. Nia HT,
     3. Liu H,
     4. Seano G,
     5. Datta M,
     6. Jones D,
     7. Rahbari N, et al.

     Solid stress and elastic energy as measures of tumour mechanopathology. Nat Biomed Eng. 2016; 1.
103. 103.↵
     2. Stylianopoulos T,
     3. Martin JD,
     4. Chauhan VP,
     5. Jain SR,
     6. Diop-Frimpong B,
     7. Bardeesy N, et al.

     Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012; 109: 15101–8.

     OpenUrlAbstract/FREE Full Text
104. 104.↵
     2. Thurber GM,
     3. Schmidt MM,
     4. Wittrup KD.

     Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008; 60: 1421–34.

     OpenUrlCrossRefPubMedWeb of Science
105. 105.↵
     2. Thurber GM,
     3. Wittrup KD.

     Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 2008; 68: 3334–41.

     OpenUrlAbstract/FREE Full Text
106. 106.↵
     2. Miers L,
     3. Lamborn K,
     4. Yuan A,
     5. Richman C,
     6. Natarajan A,
     7. DeNardo S, et al.

     Does paclitaxel (taxol) given after 111In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res. 2005; 11: 7158s–63s.

     OpenUrlAbstract/FREE Full Text
107. 107.↵
     2. Jang JK,
     3. Khawli LA,
     4. Park R,
     5. Wu BW,
     6. Li Z,
     7. Canter D, et al.

     Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther. 2013; 12: 2827–36.

     OpenUrlAbstract/FREE Full Text
108. 108.↵
     2. Simon N,
     3. Antignani A,
     4. Hewitt SM,
     5. Gadina M,
     6. Alewine C,
     7. FitzGerald D.

     Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight. 2019; 4.
109. 109.↵
     2. Beyer I,
     3. van Rensburg R,
     4. Strauss R,
     5. Li Z,
     6. Wang H,
     7. Persson J, et al.

     Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res. 2011; 71: 7080–90.

     OpenUrlAbstract/FREE Full Text
110. 110.↵
     2. Arribas J,
     3. Borroto A.

     Protein ectodomain shedding. Chem Rev. 2002; 102: 4627–38.

     OpenUrlCrossRefPubMedWeb of Science
111. 111.↵
     2. Zhang Y,
     3. Pastan I.

     High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res. 2008; 14: 7981–6.

     OpenUrlAbstract/FREE Full Text
112. 112.↵
     2. Abuqayyas L.

     Evaluation of the mechanistic determinants for IgG exposure in tissues. University at Buffalo, 2012; Ph.D Thesis.
113. 113.↵
     2. Pool M,
     3. Kol A,
     4. Lub-de Hooge MN,
     5. Gerdes CA,
     6. de Jong S,
     7. de Vries EG, et al.

     Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. Oncotarget. 2016; 7: 68111–21.

     OpenUrl
114. 114.↵
     2. Iwano J,
     3. Shinmi D,
     4. Masuda K,
     5. Murakami T,
     6. Enokizono J.

     Impact of different selectivity between soluble and membrane-bound forms of carcinoembryonic antigen (CEA) on the target-mediated disposition of anti-CEA monoclonal antibodies. Drug Metab Dispos. 2019; 47: 1240–6.

     OpenUrlAbstract/FREE Full Text
115. 115.↵
     2. Awuah P,
     3. Bera TK,
     4. Folivi M,
     5. Chertov O,
     6. Pastan I.

     Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins. Mol Cancer Ther. 2016; 15: 1648–55.

     OpenUrlAbstract/FREE Full Text
116. 116.↵
     2. Zhang Y,
     3. Xiang L,
     4. Hassan R,
     5. Pastan I.

     Immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A. 2007; 104: 17099–104.

     OpenUrlAbstract/FREE Full Text
117. 117.↵
     2. Fujimori K,
     3. Covell DG,
     4. Fletcher JE,
     5. Weinstein JN.

     A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990; 31: 1191–8.

     OpenUrlAbstract/FREE Full Text
118. 118.↵
     2. Rhoden JJ,
     3. Wittrup KD.

     Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci. 2012; 101: 860–7.

     OpenUrlCrossRefPubMed
119. 119.
     2. Juweid M,
     3. Neumann R,
     4. Paik C,
     5. Perez-Bacete MJ,
     6. Sato J,
     7. van Osdol W, et al.

     Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992; 52: 5144–53.

     OpenUrlAbstract/FREE Full Text
120. 120.↵
     2. Lee CM,
     3. Tannock IF.

     The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010; 10: .
121. 121.↵
     2. Singh AP,
     3. Guo L,
     4. Verma A,
     5. Wong GG-L,
     6. Thurber GM,
     7. Shah DK.

     Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation. AAPS J. 2020; 22: 28.

     OpenUrl
122. 122.
     2. Pak Y,
     3. Zhang Y,
     4. Pastan I,
     5. Lee B.

     Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 2012; 72: 3143–52.

     OpenUrlAbstract/FREE Full Text
123. 123.↵
     2. Cilliers C,
     3. Menezes B,
     4. Nessler I,
     5. Linderman J,
     6. Thurber GM.

     Improved tumor penetration and single-cell targeting of antibody–drug conjugates increases anticancer efficacy and host survival. Cancer Res. 2018; 78: 758–68.

     OpenUrlAbstract/FREE Full Text
124. 124.↵
     2. Adams GP,
     3. Schier R,
     4. Marshall K,
     5. Wolf EJ,
     6. McCall AM,
     7. Marks JD, et al.

     Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998; 58: 485–90.

     OpenUrlAbstract/FREE Full Text
125. 125.↵
     2. Adams GP,
     3. Schier R,
     4. McCall AM,
     5. Simmons HH,
     6. Horak EM,
     7. Alpaugh RK, et al.

     High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 2001; 61: 4750–5.

     OpenUrlAbstract/FREE Full Text
126. 126.↵
     2. Engler FA,
     3. Polli JR,
     4. Li T,
     5. An B,
     6. Otteneder M,
     7. Qu J, et al.

     “Catch-and-release” anti-carcinoembryonic antigen monoclonal antibody leads to greater plasma and tumor exposure in a mouse model of colorectal cancer. J Pharmacol Exp Ther. 2018; 366: 205–19.

     OpenUrlAbstract/FREE Full Text
127. 127.↵
     2. Hosono MN,
     3. Hosono M,
     4. Endo K,
     5. Ueda R,
     6. Onoyama Y.

     Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J Nucl Med. 1994; 35: 504–9.

     OpenUrlAbstract/FREE Full Text
128. 128.
     2. Hauck ML,
     3. Zalutsky MR.

     Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: part I: timing of injection relative to hyperthermia. Int J Hyperthermia. 2005; 21: 1–11.

     OpenUrlCrossRefPubMed
129. 129.↵
     2. Hauck ML,
     3. Dewhirst MW,
     4. Bigner DD,
     5. Zalutsky MR.

     Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res. 1997; 3: 63–70.

     OpenUrlAbstract
130. 130.↵
     2. Khaibullina A,
     3. Jang BS,
     4. Sun H,
     5. Le N,
     6. Yu S,
     7. Frenkel V, et al.

     Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med. 2008; 49: 295–302.

     OpenUrlAbstract/FREE Full Text
131. 131.
     2. Thomas VA,
     3. Balthasar JP.

     Sorafenib decreases tumor exposure to an anti-carcinoembryonic antigen monoclonal antibody in a mouse model of colorectal cancer. AAPS J. 2016; 18: 923–32.

     OpenUrl